ライフサイエンスコーパス: study entry

1 at was frequency matched by decade of age at study entry.

2 omen attempting pregnancy for </=6 cycles at study entry.

3 tients had infradiaphragmatic involvement at study entry.

4 were positive for meningococcal carriage at study entry.

5 or CRC who were not adherent to screening at study entry.

6 outcome was CRC screening within 6 months of study entry.

7 a median duration of epilepsy of 25 years at study entry.

8 gic failure was associated with higher VL at study entry.

9 rospectively over the 18-month period before study entry.

10 ervation, 722 (21%) were age </= 40 years at study entry.

11 l consistency, was initially administered at study entry.

12 associated with fasting insulin measured at study entry.

13 othelin-receptor antagonists, was allowed at study entry.

14 phase FISH (iFISH) analysis was performed at study entry.

15 rticipants reported moderate to severe HF at study entry.

16 or immunosuppressive therapy was allowed at study entry.

17 ory of artificial tear use within 30 days of study entry.

18 -two patients (27%) were age >/= 70 years at study entry.

19 59.8 +/- 11.5 y) underwent (18)F-FDG PET at study entry.

20 point was disease remission at 6 months from study entry.

21 er causes occurring fewer than 120 days from study entry.

22 emoved and without clinical signs of BCRL at study entry.

23 te (MTX) or with substantial MTX toxicity at study entry.

24 munizations, with a boost 6 to 8 months from study entry.

25 gimens), and 45% had extrahepatic disease at study entry.

26 free of cancer and cardiovascular disease at study entry.

27 All patients had progressive disease before study entry.

28 progressing from dexamethasone treatment at study entry.

29 onsuming low-, medium-, and high-ED diets at study entry.

30 were at least 70 years of age at the time of study entry.

31 (1c)) measurements taken in the years before study entry.

32 lence of cervical HPV infection was 25.6% at study entry.

33 progression at a median of 43.4 months from study entry.

34 ue to experience FFP 20+ to 50+ months after study entry.

35 lergic disease and had no eczema symptoms at study entry.

36 ed by means of biopsy within 12 months after study entry.

37 erapy completed more than 12 months prior to study entry.

38 chymal fraction (BPF) was 0.825 +/- 0.015 at study entry.

39 ansplantation-Specific Comorbidity Index, at study entry.

40 years, and weight change between age 21 and study entry.

41 men, 3816 (47%) had erectile dysfunction at study entry.

42 -alpha to imatinib mesylate within a year of study entry.

43 myocardial infarction (MI) or stroke before study entry.

44 te of treatment failure 7 to 63 months after study entry.

45 on-year for men with erectile dysfunction at study entry.

46 disease recurrence or metastatic disease at study entry.

47 rgical revascularisation in the month before study entry.

48 atory cells from tumour biopsies provided at study entry.

49 ompared with subjects with low VWF levels at study entry.

50 ere determined in plasma samples obtained at study entry.

51 s of whole blood during the 3 days following study entry.

52 experienced depression within 2 years after study entry.

53 ime scale can be set to start at birth or at study entry.

54 ntagonists, or had no follow-up visits after study entry.

55 .5) predictions at participant residences at study entry.

56 aving an eosinophil count of 2% or higher at study entry.

57 ibitors or ARBs, for at least 8 weeks before study entry.

58 ession by RECIST criteria within 7 months of study entry.

59 or sham based on prior treatment for DME at study entry.

60 ll women had an intact uterus at the time of study entry.

61 o 34, 35 to 44, and 45 to 65 years of age at study entry.

62 th antipsychotics did not exceed 6 months at study entry.

63 0 IU/m(2) weekly), beginning at week 7 after study entry.

64 an rCBV than nontransformers at the point of study entry (1.93 vs 1.31).

65 6%) of the cohort died during follow-up from study entry (10 years after cure).

66 The BMI was calculated at the time of study entry (12 to 18 weeks of gestation).

67 Assessments were done at study entry, 12 months, and 24 months.

68 ng 1495 patients was 53 years at the time of study entry; 157 (11%) had axillary node-negative diseas

69 1 participants aged 73 years (on average) at study entry (1981-1985), 11,203 died during 23 years of

70 Health Study, were free of CVD and angina at study entry (1992-1995), and who had information on self

71 em food frequency questionnaire completed at study entry (1995-1996) with the MyPyramid Equivalents D

72 the 4247 men without erectile dysfunction at study entry, 2420 men (57%) reported incident erectile d

73 ho had received more than 6 months of ADT at study entry (3.7% v 2.0%; P = .0645).

74 tinuous remission in progress at the time of study entry; (3) receiving self-, parent-, or caregiver-

75 At study entry, 350 boys had serum OCPs measured.

76 02.4 mum vs 397.6 +/- 96.5 mum, P = 0.002 at study entry; 381.2 +/- 106.6 mum vs 364 +/- 101.2 mum, P

77 ion Study were followed up for 5 years after study entry (44.6% of the original Treatment for Adolesc

78 talized for heart failure in the year before study entry (47% vs. 28%, p = 0.004) and had a higher in

79 pants (6103 screening studies; median age at study entry, 54.0 years; range, 25-91 years), 1454 had u

80 tients (175 men and 166 women; median age at study entry, 62 years) in the 1-year group and 60 years

81 At study entry, 64% of subjects had VWF antigen (VWF:Ag) or

82 nts were receiving concomitant treatments at study entry, 69 of whom attempted to reduce them; 65% (4

83 patients with axis I depressive disorders at study entry; 73 had depressive personality disorder.

84 In the year after study entry, 84.8% of women (n = 173) returned for a sub

85 Of 1,469 participants symptomatic at study entry, 858 (58.4%) subsequently achieved recovery.

86 d GIST and without macroscopic metastases at study entry (93.4% v 86.8%; HR, 0.53; 95% CI, 0.30 to 0.

87 ed at AIDs Clinical Trial Group (ACTG) A5230 study entry, a study of lopinavir/ritonavir (LPV/r) mono

88 onship between pollutants and measured BP at study entry, adjusting for cardiovascular disease risk f

89 However, we discontinued study entry after five serious adverse events were obser

90 ician performed tympanometry and otoscopy at study entry, after 3 and 7 days, and then weekly until b

91 and brain magnetic resonance (MR) imaging at study entry, after the first 12-week period, and at stud

92 Median levels of NT-proBNP were higher at study entry among incident cases (120.3 ng/l [interquart

93 ted C-peptide concentration >/=0.2 nmol/L at study entry among subjects with up to a 5-year diabetes

94 in this analysis, 34 receiving apheresis at study entry and 14 younger than 18 years.

95 ontrast visual acuity, and SD OCT imaging at study entry and 3 and 6 months.

96 ger association between increased glucose at study entry and adenoma recurrence (OR, 1.78; 95% CI, 1.

97 psies of 45 patients with CMT1A, obtained at study entry and after 24-months of treatment either with

98 At study entry and after 5 years, clinical and MRI (ie, gra

99 nd Self-Rated Health scales were assessed at study entry and annually thereafter; linear mixed models

100 lmologic examination, including swept-OCT at study entry and at 7 days and 30 days after treatment wi

101 keratometry reading (Kmax) were measured at study entry and at the 12-month follow-up.

102 merular filtration rate (GFR) 52 weeks after study entry and biopsy-proven rejection.

103 cale (GSRS) was completed by all patients at study entry and by treatment-naive patients after PPI th

104 lmonary TB treated at least 12 months before study entry and considered cured.

105 fected for differences in gene expression at study entry and daily for 3 days prior to conversion to

106 Cognition Study who did not have dementia at study entry and developed incident dementia during follo

107 nt follow-up was 11.8 years (IQR 17-26) from study entry and did not differ between countries.

108 al menopause) who were 40-98 years of age at study entry and did not have a history of breast cancer.

109 individual propensity scores for MTX use at study entry and during followup in a time-varying manner

110 At study entry and during followup, total Sharp scores (TSS

111 nd medical information were collected at the study entry and every 2 years during follow-up visits.

112 At study entry and every 3 months through 2 years, particip

113 cholesterol and use of CLM were measured at study entry and every 6 months up to 5.5 years.

114 number of hospital visits, and time between study entry and exit.

115 orted dieting at study entry were heavier at study entry and gained more weight over time than did no

116 Complications Study who were free of CAD at study entry and had DNA available were selected (n = 453

117 idepressant use or mania symptom load at the study entry and mania or depression symptom severity at

118 fidaxomicin, and 44 received vancomycin) at study entry and on days 4, 10, 14, 21, 28, and 38 for qu

119 sely correlated with interleukin-6 levels at study entry and over the first 5 days of management of s

120 d functional assessments were carried out at study entry and repeated annually over a 3-year observat

121 rne SPCs and the cellular content of HIFs at study entry and the first-week follow-up visit predicted

122 Participants self-reported alcohol use at study entry and then again after 15, 20, and 25 years.

123 1,831 subjects who did not have dementia at study entry and then did or did not develop incident dem

124 Echocardiograms were obtained 1 year after study entry and then every 2 years; BP was measured annu

125 stula vs. graft) in hemodialysis patients at study entry and time from placement until primary and se

126 als for patients with more severe disease at study entry and to worsen for patients with less severe

127 improve in those with more severe disease at study entry and to worsen in those with less severe dise

128 Clinical features at study entry and treatment outcomes were evaluated in pat

129 fee-for-service insurance coverage prior to study entry and using either a fixed-window or all-avail

130 ar among men without erectile dysfunction at study entry and was 0.024 per person-year for men with e

131 6 weeks and tumour tissue biopsy was done at study entry and was optional after disease progression.

132 Participants were at least 60 years old at study entry and were enrolled at 130 SELECT sites, and C

133 Among subjects without depression at study entry and without dementia or significant cognitiv

134 children with diabetes (4-10 years of age at study entry) and 69 age-matched control subjects at two

135 ard operating procedures, fixed criteria for study entry, and common reagents, to optimize combined a

136 ypercortisolism for a minimum of 10 years at study entry, and continuing to be cured with no relapses

137 tched by age, sex, race/ethnicity, timing of study entry, and sample selection.

138 progressive brain metastases at the time of study entry; and those with leptomeningeal disease.

139 Remission, defined as the absence of all study entry anxiety disorders.

140 Ages at milestones that occur prior to study entry are left censored if individuals are enrolle

141 ts in 19 IRIS and 39 control participants at study entry, ART initiation, and IRIS and used condition

142 vel, serum albumin level, and non-TB AIDS at study entry, as well as for time-varying CD4 cell count,

143 At study entry at average age of 10 years, residential near

144 the clinic visit closest to 12 months after study entry) at the patient and clinic levels.

145 enal function measured in the 2 years before study entry, based on at least three measurements over a

146 ess and macular volume were assessed once at study entry (baseline) by optical coherence tomography (

147 ma exacerbations within the 12 months before study entry, baseline asthma medications, geographic reg

148 b infusions, at 6 and 8 weeks (14 weeks from study entry) before initiating another DMT.

149 rtality associated with self-reported BMI at study entry, BMI at age 21 years, and weight change betw

150 For those who were symptomatic at study entry but subsequently achieved recovery, time to

151 specialist shoulder clinician 3 months after study entry, but no intervention).

152 duction in invited women aged 40-49 years at study entry, but this finding could be due in part to sc

153 Serum anticholinergic activity, measured at study entry by radioreceptor assay, was available for 49

154 tection of NVP resistance in plasma virus at study entry by standard population genotype was strongly

155 window could retrospectively be predicted at study entry by the ability of CD8(+) T cells to gain acc

156 ed pressure wave, and reservoir pressure) at study entry compared with subjects without improvement (

157 ficantly inferior overall survival (OS) from study entry compared with white children (37%+/- 9% vs 4

158 A total of 491 patients met study entry criteria with 353 IH cases and 138 OH cases.

159 age, 80.1 years [10.7], 70.5% women) who met study entry criteria, overall mortality at 30 days was 7

160 A total of 16,527 patients met all study entry criteria.

161 spite the reliance on behavioral measures as study entry criteria.

162 One hundred thirty-eight cases met study entry criteria; the overall mortality was 62% (85

163 llow-up scans in 5 PDD subjects at 2 y after study entry demonstrated a significant interval within-s

164 hereas those receiving HCQ who had damage at study entry did not (HR 1.106 [95% CI 0.70-1.74]) (P = 0

165 ex, blood pressure, and diabetes mellitus at study entry did not have a large effect on these estimat

166 ivariate analysis, 11.7% with Hb <11 g/dl at study entry died versus 5% of those with initial Hb > or

167 l-2 fusion transcripts in the bone marrow at study entry experienced continuous molecular remission.

168 tricular ejection fraction (LVEF) >/= 55% at study entry following neoadjuvant chemotherapy with or w

169 t coreceptor use at both study screening and study entry for 118 treatment-experienced subjects in AI

170 In contrast, PFS at 4 years from study entry for patients with FLT3/ITD was inferior to t

171 al event-free survival (EFS) at 4 years from study entry for those patients with and without FLT3/ITD

172 udy and 1076 individuals < or = 50 of age at study entry from the Multi-Ethnic Study of Atheroscleros

173 At study entry, gray lesion was associated with exudative f

174 Subjects whose VWF testing was normal at study entry had a similar rate of sequence variations as

175 patients receiving HCQ who had no damage at study entry had a statistically significant decrease in

176 Compared with controls, patients with CDI at study entry had counts of major microbiome components th

177 ticipants who lost weight between age 21 and study entry had increased mortality regardless of their

178 ent of patients who were alive 5 years after study entry had not received radiation therapy.

179 sed risk of recurrent HGAIN at 2 years after study entry (HR .47; 95% CI, .22-1.00; P = .05).

180 sed risk of recurrent HGAIN at 2 years after study entry (HR 4.06; 95% confidence interval [CI], 1.58

181 d to controls, cases displayed elevations at study entry in interleukin (IL) 8, T-helper (Th) 1 (IL-2

182 In addition, PET scores at study entry in MCI patients significantly predict clinic

183 BMC samples from 181 maraviroc recipients at study entry in MOTIVATE or A4001029 (51% R5 by original

184 tandard genotype were detected more often at study entry in NNRTI-experienced patients than NNRTI-nai

185 prostate cancer diagnosis and mortality from study entry (in waves from 1967 to 1987) through 2009.

186 Front-line therapies for PTLD before study entry included immune suppression reduction or wit

187 ssociation functional class I/II symptoms at study entry, including 249 in whom left ventricular outf

188 47 of 72 patients not on apheresis at study entry increased evolocumab dosing to every 2 weeks

189 Reduced reward learning at study entry increased the odds of a persisting diagnosis

190 igen SOX2 and preserved humoral responses at study entry independently correlated with reduced risk o

191 Ciprofloxacin used at study entry independently predicted invasive Candida inf

192 men with CH-B (n = 337) or CH-C (n = 343) at study entry into the MACS were prospectively followed to

193 iovascular risk factors and comorbidities at study entry (mean [SD], 8.57 [6.55] years after transpla

194 At study entry, mean choroidal thickness measured in the ce

195 beta-HPV DNA positive, with 1 to 13 types at study entry (median, 4.0 types).

196 oon after HIV-1 infection, from the level at study entry (median, 495 cells per cubic millimeter; int

197 At study entry, median age was 11 months (interquartile ran

198 At study entry, median BLL was 3 mug/dL (range, < 0.5-31 mu

199 At study entry, median body mass index was high (29.2 kg/m(

200 At study entry, median maternal age was 28 y (interquartile

201 bin and phosphorus, and log(10) M30 value at study entry most accurately identified patients who woul

202 After study entry (n = 1866), parents of eligible infants (n =

203 ty outcomes among those with moderate CKD at study entry (n = 3,267) with those with baseline eGFR >o

204 Men with </= 6 months of ADT at study entry (n = 36) had a greater rate of decrease in L

205 itive urine drug or breath alcohol screen at study entry (N=228) (odds ratio=2.18, 95% CI=1.30, 3.68)

206 At study entry, NIH skin score 3 and Lee skin symptom score

207 Study entry OCT values were similar in both treatment gr

208 udotyping is a useful and safe technique for studying entry of emerging strains of influenza virus.

209 8063 (85%) had no cardiovascular disease at study entry; of these men, 3816 (47%) had erectile dysfu

210 The effect of treatment received at study entry on survival was determined.

211 rty-nine vaccine recipients were assessed at study entry; on the day of the third vaccination; at 24

212 s 0 and 14 and at months 6, 12, and 18 after study entry or daily azathioprine until month 22.

213 survival (OS) were assessed from the date of study entry or random assignment, as appropriate.

214 213 participants who received ART soon after study entry or sometime thereafter and had a suppressed

215 At study entry, participants estimated the age at which the

216 on, formal education, clinical diagnosis for study entry, patient history, and concomitant medication

217 At study entry, patients were stratified according to the s

218 Although at study entry, patients with PaO2/FIO2 less than 150 had a

219 me dose and schedule as last received before study entry, plus cetuximab 400 mg/m2 loading dose, then

220 hromosomal abnormalities detected by FISH at study entry predicted overall survival.

221 s between trough tacrolimus concentration at study entry (r=-0.56; P=0.01) and 3-month tacrolimus exp

222 atment; 6 eyes without exudative features at study entry received deferred treatment (after 1 month o

223 Twenty-four eyes with exudative features at study entry received prompt treatment; 6 eyes without ex

224 ith microscopic or gross residual disease at study entry received RT.

225 Study entry required hospitalization within the previous

226 ults 40 years and older vs < 40 years old at study entry, respectively), and participants who were no

227 on, and the TNF pathway were measured in the study entry samples.

228 x (-5%) and hippocampus (-3%), compared with study entry scans.

229 Analyses in women age 50 years or older on study entry showed benefits of clodronate for recurrence

230 At study entry, significant differences between groups were

231 FcepsilonRIalpha mRNA expression measured on study entry significantly improved an existing model of

232 ts, and 8 of 9 participants receiving FIX at study entry stopped prophylaxis.

233 At study entry, subjects had a median reduction in HIV RNA

234 y excluding participants who had dementia at study entry, subsequently developed dementia during the

235 accounting for important variables known at study entry such as tumor location and histology, female

236 Of the 177 patients who met the criteria for study entry, the majority were women (80%) and African A

237 .8%] African American) aged 5 to 19 years at study entry, the mean age of peak height velocity was 13

238 At study entry, the mean MRSS value was 21.0 in the D-Pen T

239 At study entry, the mean time on dialysis among recipients

240 At study entry, the median HIV viral load was 12,759 copies

241 When results were stratified by age at study entry, the risk of AD was only significantly incre

242 At study entry there was no significant difference in CSF o

243 At study entry these patients had reduced CSF amyloid Ass1-

244 re not receiving corticosteroid treatment at study entry; those in cohort B were symptomatic and on a

245 se CNS disease is radiographically stable at study entry; those with active brain metastases, defined

246 t limitation were proxy appointment prior to study entry (time of tracheotomy/RCU transfer) (odds rat

247 olinium-enhancing lesions (metformin, 1.8 at study entry to 0.1 at month 24; pioglitazone, 2.2 at stu

248 try to 0.1 at month 24; pioglitazone, 2.2 at study entry to 0.3 at month 24).

249 w or enlarging T2 lesions (metformin, 2.5 at study entry to 0.5 at month 24; pioglitazone, 2.3 at stu

250 try to 0.5 at month 24; pioglitazone, 2.3 at study entry to 0.6 at month 24), as well as of gadoliniu

251 From study entry to 18 months before RRT, GFR declined 7% fas

252 of 18 +/- 30 (median 10) in the year before study entry to 2.0 +/- 4.3 (median 0) at a median follow

253 treatment interval increased from 35 days at study entry to 63 days at 12 months and was 60 days at 3

254 m was conducted at 6 and 12 months following study entry to assess for infection.

255 Mean changes in CASI Z scores from study entry to assessment at years 1 (n=2472), 2 (n=1968

256 ants were analyzed by allele-specific PCR at study entry to quantify NVP-resistant mutants down to 0.

257 ned patients who had adenomas removed before study entry to receive placebo (679 patients) or 200 mg

258 Relapsed/refractory disease at study entry, TP53 aberration, advanced Rai stage, and hi

259 l endpoints such as survival time (time from study entry until death).

260 in (TBP) measured by neutron activation from study entry until immediately prior to LT was the primar

261 asma or serum candidate proteins measured on study entry using Myriad-RBM multiplex panels.

262 xis II comparison subjects) were assessed at study entry using the cognitive section of the Revised D

263 olony-forming units [CFU]) of 6.7 +/- 2.0 at study entry; vancomycin treatment consistently reduced C

264 ce mutation associations with subtype, site, study entry VL, and CD4 were evaluated using Fisher exac

265 The LVEF at study entry was 0.35 +/- 0.10, 0.51 +/- 0.11 at 6 months

266 Median overall survival from study entry was 5.7 months (range, 0.7 to 28+ months).

267 Mean age at study entry was 63.4 years (SD 8.6).

268 The median age at study entry was 64.5 years (range, 49.8 to 80.9 years).

269 The median BDI-II score at study entry was 8, with 28% of the sample having BDI-II

270 Progression-free survival (PFS) from study entry was analyzed by the Cox regression model.

271 or obese (RR = 1.25, 95% CI: 1.13, 1.38) at study entry was associated with increased mortality.

272 cogenic HPV genotypes within 8 months before study entry was associated with increased risk of recurr

273 nts, a ventricular pre-excitation pattern at study entry was associated with markedly increased volta

274 of weight change per decade from midlife to study entry was greater for participants who developed i

275 tuximab treatment, the mean level of IAAs at study entry was markedly lower (P = 0.035) for patients

276 Choroidal thickness at study entry was significantly thicker in the study eyes

277 Median survival from study entry was similar for women (31 years; IQR 19-38)

278 increases in subjects who lost 6% or more of study entry weight.

279 mal cognition (n = 2587) or MCI (n = 482) at study entry were assessed every 6 months for incident de

280 ere LV dysfunction and greater remodeling at study entry were associated with less recovery.

281 participants with undetectable HIV-1 RNA at study entry were detectable (43 and 47 copies/mL) at wee

282 Baseline data at study entry were examined with respect to final outcome

283 trols with a history of head injury prior to study entry were excluded.

284 ersons diagnosed with IBS before the date of study entry were excluded.

285 lar cortical volume (p < 0.001, OR = 0.2) at study entry were found to predict the changing clinical

286 Women who reported dieting at study entry were heavier at study entry and gained more

287 an age 63 years [SD 11]) with CASI scores at study entry were included in the analysis, with a median

288 aive participants without liver cirrhosis at study entry were included.

289 Prescription data at study entry were obtained from 404 participants in the R

290 Levels of sTNFRI and sTNFRII at study entry were quantified using enzyme-linked immunoso

291 ion therapy was initiated within 6 months of study entry were randomly assigned in a blinded 1:1 rati

292 ants who had never been intubated before the study entry were selected.

293 he risk factors for current atopic asthma at study entry were sensitization (adjusted odds ratio [OR]

294 and who did not report suicidal ideation at study entry were subsequently treated with citalopram hy

295 BsAg), anti-HCV, and serum HCV RNA levels at study entry were tested.

296 g stable doses of antiepileptic drugs before study entry, were enrolled in an expanded-access program

297 iland, the majority of whom were on HAART at study entry, were prospectively followed semiannually fo

298 CRP concentrations were measured at study entry with a point-of-care assay using whole blood

299 nduction abnormalities on the 12-lead ECG at study entry with occurrence of VT/VF in 431 patients wit

300 was to minimize the percentage of persons at study entry with self-reported CHD (previous myocardial